Business · 04/05/2016Updated: 10/17/2026 · 1 min read
FDA Announces Draft Guidance for Direct-Acting Antiviral Drugs for Chronic Hepatitis C Treatment
Summary
The FDA is releasing a revised draft guidance to help pharmaceutical companies develop effective treatments for chronic hepatitis C using direct-acting antiviral drugs.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →